Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Common Equity: 2019-2025

Historic Common Equity for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $372.3 million.

  • Nurix Therapeutics' Common Equity fell 1.22% to $372.3 million in Q3 2025 from the same period last year, while for Aug 2025 it was $372.3 million, marking a year-over-year decrease of 1.22%. This contributed to the annual value of $527.0 million for FY2024, which is 162.85% up from last year.
  • As of Q3 2025, Nurix Therapeutics' Common Equity stood at $372.3 million, which was down 16.83% from $447.6 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Common Equity ranged from a high of $527.0 million in Q4 2024 and a low of $168.7 million during Q1 2024.
  • For the 3-year period, Nurix Therapeutics' Common Equity averaged around $337.5 million, with its median value being $370.7 million (2024).
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 38.42% in 2024, then spiked by 184.99% in 2025.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' Common Equity stood at $342.3 million in 2021, then fell by 11.28% to $303.7 million in 2022, then tumbled by 33.98% to $200.5 million in 2023, then soared by 162.85% to $527.0 million in 2024, then decreased by 1.22% to $372.3 million in 2025.
  • Its Common Equity stands at $372.3 million for Q3 2025, versus $447.6 million for Q2 2025 and $480.9 million for Q1 2025.